Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial

Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients

(2014) R. Attanasio et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management

(2014) Wybrich R Cnossen et al.   Orphanet Journal of Rare Diseases

Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

(2013) Esther Meijer et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data

(2013) Tom J.G. Gevers et al.   GASTROENTEROLOGY

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

(2013) Anna Caroli et al.   LANCET

Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume

(2013) Titus F. M. Wijnands et al.   LIVER INTERNATIONAL

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

(2012) M. C. Hogan et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

(2012) Tom JG Gevers et al.   BMC Nephrology

The long-term outcome of patients with polycystic liver disease treated with lanreotide

(2011) M. Chrispijn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: the pathophysiology and management of polycystic liver disease

(2011) F. Temmerman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide

(2010) A. Caroli et al.   Clinical Journal of the American Society of Nephrology

Somatostatin analogues for treatment of polycystic liver disease

(2010) Tom JG Gevers et al.   CURRENT OPINION IN GASTROENTEROLOGY

Medical and surgical treatment options for polycystic liver disease1

(2010) Joost P.H. Drenth et al.   HEPATOLOGY

Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease

(2010) M. C. Hogan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Cyst Infections in Patients with Autosomal Dominant Polycystic Kidney Disease

(2009) M. Sallee et al.   Clinical Journal of the American Society of Nephrology

Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial

(2009) Loes van Keimpema et al.   GASTROENTEROLOGY

Somatostatin analogues reduce liver volume in polycystic liver disease

(2008) L van Keimpema et al.   GUT

Unified Criteria for Ultrasonographic Diagnosis of ADPKD

(2008) Y. Pei et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY